M&A Deal Summary

Astellas Pharma Acquires Propella

On November 15, 2023, Astellas Pharma acquired life science company Propella

Acquisition Highlights
  • This is Astellas Pharma’s 13th transaction in the Life Science sector.
  • This is Astellas Pharma’s 11th transaction in the United States.
  • This is Astellas Pharma’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2023-11-15
Target Propella
Sector Life Science
Buyer(s) Astellas Pharma
Deal Type Add-on Acquisition
Advisor(s) Stifel, Nicolaus & Co., Inc. (Financial)
Cooley (Legal)

Target

Propella

Pittsboro, North Carolina, United States
Propella is a biopharmaceutical company that has developed a platform that combines medicinal chemistry with lymphatic targeting to create best- or first-in-class oncology drugs that have validated MOAs and biological targets but suffer from efficacy and safety limitations. Lymphatic targeting enables therapies to be delivered directly to therapeutic target tissues including the lymph nodes and bone, thereby enhancing efficacy and bypassing plasma compartment safety and efficacy limitations and first-pass liver effects. Propella is based in Pittsboro, North Carolina.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Astellas Pharma

Tokyo, Japan
Category Company
Founded 1923
Sector Life Science
Employees14,754
Revenue 1.60T JPY (2024)
DESCRIPTION
Astellas office complex in Northbrook, Illinois.
Astellas office complex in Northbrook, Illinois.

Astellas Pharma is a pharmaceutical company committed to the therapeutic fields of urology, immunology, oncology, neuroscience and DM complications and metabolic diseases. Astellas Pharma was incorporated in 1923 and is based in Tokyo, Japan.

DEAL STATS #
Overall 14 of 14
Sector (Life Science) 13 of 13
Type (Add-on Acquisition) 14 of 14
State (North Carolina) 1 of 1
Country (United States) 11 of 11
Year (2023) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-04-30 IVERIC bio

Cranbury, New Jersey, United States

IVERIC bio is a biopharmaceutical company specializing in the development of novel therapeutics to treat ophthalmic diseases, with a focus on orphan and age-related retinal diseases. IVERIC bio was founded in 2007 and is based in Cranbury, New Jersey.

Buy $5.9B
Mergr

Product

Company

Legal